Featured News

Today, the U.S. Food and Drug Administration issued a final rule for gluten-free labeling compliance requirements for fermented and hydrolyzed foods.

The ACeD Study is looking for volunteers with celiac disease to participate in a phase 1 clinical trial testing the investigational drug KAN-101.

We are pleased to announce our newest online resource for patients and caregivers to drive policy change to improve the health of those living with celiac disease and accelerate research: iAdvocate.

CDF has been approved for a $100,000 funding award through the Eugene Washington PCORI Engagement Awards program. The funds will support the community convening of patient advocates, researchers, and other key stakeholders to create a roadmap for patient advocate engagement in research.

People with celiac disease have a 10-fold greater risk for inflammatory bowel disease (IBD). Those with IBD have a 4-fold greater risk for celiac disease. A new study reviews the link between these two autoimmune disorders.

TAK-062, an orally administered synthetic enzyme that survives the acidity of the stomach and digests gluten effectively, has passed its phase 1 clinical drug trial, indicating it is safe to use in celiac patients.

Showcasing the “brightest ideas and breakthroughs in digestive disease,” DDW 2020 includes recent studies and innovations in celiac disease and gluten-related disorders, some of which we have curated and summarized for you.

A small pilot study suggests chemical pollutants might be an environmental factor associated with celiac disease in children. This is the first research to link the autoimmune disorder with persistent organic pollutants (POPs) detected in blood samples from celiac patients.

2020 marks the 30th Anniversary for the Celiac Disease Foundation. We're celebrating 30 years with a highlight reel of CDF's most notable yearly accomplishments, posted each day throughout the month of May on CDF’s Facebook & Twitter.

The first mice with characteristics of celiac disease have been developed at the University of Chicago Celiac Disease Center. For the first time researchers can observe celiac disease onset as the mouse’s immune system launches a coordinated attack against gluten.